VSIG4: A Protein Implicated in Autoimmune Diseases (G11326)

Target Name: VSIG4

NCBI ID: G11326

VSIG4

VSIG4: A Protein Implicated in Autoimmune Diseases

VSIG4 (Protein Z39Ig), also known as Z39Ig, is a type of immunoglobulin or Ig, which is a protein produced by B cells in the human body. It is a single chain protein with four constant (C) regions and one variable (V) region. The variable region of VSIG4 contains a unique genetic sequence that is specific to this protein and gives it its unique identifier, Z39Ig.

VSIG4 is a type of autoimmune disease in which the immune system attacks and destroys normal tissue. One of the hallmark features of this disease is the production of antibodies, particularly IgG antibodies, that recognize and attack the self-antigens of the patient. VSIG4 is an autoimmune disease that affects the skin, joints, and other tissues of the body, and it can cause significant morbidity and mortality.

The VSIG4 protein is a key player in the development and progression of VSIG4 autoimmune disease. It is involved in the regulation of immune responses and has been shown to play a critical role in the pathogenesis of VSIG4 disease. VSIG4 has been shown to interact with several other proteins, including the T-cell receptor (TCR), B-cell receptor (BCR), and the immunoglobulin G (IgG)Fc region.

VSIG4 has also been shown to play a key role in the regulation of autoimmune inflammation. It has been shown to dampen the activity of T-cells, which are critical for the development of autoimmune diseases. VSIG4 has also been shown to promote the activation and proliferation of B-cells, which are responsible for producing antibodies that contribute to the development of autoimmune diseases.

VSIG4 has been shown to play a critical role in the development of autoimmune diseases, including VSIG4 disease. VSIG4 has been shown to interact with several other proteins, including the T-cell receptor (TCR), B-cell receptor (BCR), and the immunoglobulin G (IgG)Fc region. These interactions may contribute to the regulation of immune responses and the development of autoimmune diseases.

In addition to its role in the development and regulation of autoimmune diseases, VSIG4 has also been shown to have potential as a drug target or biomarker. VSIG4 has been shown to interact with several small molecules, including inhibitors of the T-cell receptor (TCR), B-cell receptor (BCR), and the immunoglobulin G (IgG)Fc region. These interactions may make VSIG4 a potential target for small molecules that can inhibit the activity of these proteins and reduce the development of autoimmune diseases.

VSIG4 has also been shown to have potential as a biomarker for the diagnosis and monitoring of VSIG4 disease. VSIG4 levels have been shown to be elevated in the blood of patients with VSIG4 disease, and these levels can be used as a marker for the diagnosis of this disease. VSIG4 levels have also been shown to be reduced in the blood of patients who have been treated for VSIG4 disease, making them a potential biomarker for monitoring the effectiveness of treatments for this disease.

In conclusion, VSIG4 (Protein Z39Ig) is a protein that is involved in the regulation of immune responses and has been shown to play a critical role in the development and progression of VSIG4 autoimmune disease. It is also a potential drug target or biomarker for this disease. Further research is needed to fully understand the role of VSIG4 in the development and regulation of autoimmune diseases and to develop effective treatments for this disease.

Protein Name: V-set And Immunoglobulin Domain Containing 4

Functions: Phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production. Potent inhibitor of the alternative complement pathway convertases

The "VSIG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VSIG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets